BioFIT 2017, November 28-29, Strassbourg, France, meet us at booth C4
Neuroscience R&D Technologies Conference, September 28-29, London, UK - Presentation on Sept. 29
Genesis Drug Discovery, October 11-12, Frankfurt Main, Germany - Presentation on Oct. 11
BIO-Europe 2017, November 6-8, Berlin, Germany
European Brain & Behavior Society Meeting, September 8-11, Bilbao, Spain
20 Years of alpha-synuclein in Parkinsion's disease and related synucleopathies Meeting in Athens, September 7-10, 2017
EuroTau Meeting, April 27-28, Lille, France
International Conference on Alzheimer's & Parkinson’s Diseases 2017 - Booth 14a, at the entrance of the exhibition & Posters
March 29 . – April 2., Vienna, Austria
SynAging's past meetings:
Society for Neuroscience (SfN) 2016 - Posters
November 12. - 16, San Diego, USA
BIO-Europe 2016, Partnering
November 7. – 9, Cologne, Germany
3rd International Parkinson´s Disease Symposium 2016 - Booth, Symposium & Posters
October 6 - 8, Luxembourg
10th Forum of Neuroscience - Poster
July 2.-6. 2016, Copenhagen, Denmark
Alzheimer's Association International Conference 2016 - Booth 825 & Posters
July 24. – 28. 2016, Toronto, Canada
Press & Publications
SynAging's Poster won the 'Best Poster Award' here during the '20 Years of alpha-synuclein in Parkinsion's disease and related synucleopathies' meeting in Athens, September 7-10, 2017 entitled:
PATHOLOGICAL ALPHA-SYNUCLEIN PREPARATIONS INDUCE COGNITIVE IMPAIRMENT AND NEURODEGENERATION Download PDF
Poster EBBS Meeting 2017: PRION-LIKE SOLUBLE MISFOLDED PROTEIN OLIGOMERS INDUCE NEURODEGENERATION: RELEVANCE FOR PARKINSON’S AND ALZHEIMER’S DISEASE MODELS Download PDF
Dietary arachidonic acid increases deleterious effects of amyloid-β oligomers on learning abilities and expression of AMPA receptors: putative role of the ACSL4-cPLA2 balance; Link
Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy Link
ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease Link
HUMAN TAU OLIGOMERS INDUCE NEURODEGENERATION: TAUOPATHY MODELS FOR TARGET VALIDATION AND DRUG DEVELOPMENT Download PDF
HUMAN ALPHA-SYNUCLEIN OLIGOMERS BUT NOT 'SPREADING' FIBRILS INDUCE EARLY COGNITIVE DECLINE IN MICE Download PDF
SynAging's human tau oligomer poster at SFN 2016 Download PDF
SynAging's alpha synuclein oligomer poster at SFN 2016 Download PDF
SynAging's Alzheimers disease poster at AAIC 2016 Download PDF
SynAging's Parkinson's disease poster at AAIC 2016 Download PDF
True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence.
Goetghebeur PJ, Swartz JE www.ncbi.nlm.nih.gov/pubmed/27147593
Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X Download PDF, 1.3 MB
SynAging announces extension of its collaboration with Europe's largest biopharmaceutical company Download PDF
First Commercial in vitro Test System for Human Neuroprotection in Proteopathic Diseases such as Alzheimer’s and Parkinson’s Download PDF
SynAging Expands its Capabilities: Building a New Animal Facility and Hiring a Head of Pharmacology Download PDF, 150 KB
History
SynAging is a spin-off from Lorraine University in Nancy, France.
The company was founded in February 2010 by Violette Koziel (President) and Dr. Thierry Pillot (CEO/CSO) and occupies new labs on the university campus.
The company is a service organization (CRO) providing innovative models to investigate neurodegenerative diseases. SynAging’s services have been designed for pharma and biotech companies, as well as the food and nutraceutical industry.
The company has gained a high reputation for time- and cost-effective services by producing highly reproducible data and new insights in the field of proteinopathic neurodegenerative diseases.
SynAging is a revenue funded organization and has no venture captial investors.
SynAging is a spin-off from Lorraine University in Nancy, France.
+33 (0)3 83 59 58 38 
+33 (0)3 83 59 64 86
